Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) released its earnings results on Friday. The specialty pharmaceutical company reported ($0.83) EPS for the quarter, Zacks reports.
Titan Pharmaceuticals Trading Up 1.3 %
NASDAQ:TTNP opened at $3.23 on Friday. The company’s 50 day moving average price is $3.72 and its 200-day moving average price is $4.97. Titan Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $14.80.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of Titan Pharmaceuticals in a research note on Saturday. They issued a “sell” rating on the stock.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- With Risk Tolerance, One Size Does Not Fit All
- Nebius Group: The Rising Star in AI Infrastructure
- How to trade using analyst ratings
- MarketBeat Week in Review – 12/30 – 1/03
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Is The Dip in Tesla a Buying Opportunity Ahead of FSD Potential?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png&h=45&w=95&zc=2){kind=logo}
